Alberto Briganti

Active 2002–2026

Also published as
Alberto BRIGANTI
583
Papers
45,789
Citations
115
h-index
509
i10-index

Citations

Citations per year for Alberto Briganti1961: 1 citations1995: 1 citations1998: 2 citations2003: 2 citations2004: 11 citations2005: 25 citations2006: 85 citations2007: 99 citations2008: 119 citations2009: 114 citations2010: 116 citations2011: 132 citations2012: 155 citations2013: 200 citations2014: 161 citations2015: 163 citations2016: 232 citations2017: 229 citations2018: 234 citations2019: 1,188 citations2020: 1,665 citations2021: 1,512 citations2022: 1,294 citations2023: 1,014 citations2024: 1,911 citations2025: 1,005 citations2026: 30 citations1962–1994: no citations, so these years are not shown1996–1997: no citations, so these years are not shown1999–2002: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,172 citing papers, 17.6% of this breakdownItaly: 1,860 citing papers, 10.3% of this breakdownChina: 1,347 citing papers, 7.5% of this breakdownGermany: 1,270 citing papers, 7% of this breakdownUnited Kingdom: 1,144 citing papers, 6.3% of this breakdownCanada: 838 citing papers, 4.7% of this breakdownNetherlands: 783 citing papers, 4.3% of this breakdownFrance: 753 citing papers, 4.2% of this breakdownSwitzerland: 537 citing papers, 3% of this breakdownAustria: 521 citing papers, 2.9% of this breakdownSpain: 516 citing papers, 2.9% of this breakdownBelgium: 460 citing papers, 2.6% of this breakdown
0%17.6%Other 26.7%

Fields

  • Medicine85.7%
  • Biochemistry, Genetics and Molecular Biology7.9%
  • Immunology and Microbiology2%
  • Engineering0.9%
  • Computer Science0.8%
  • Psychology0.7%
  • Other2%

Topics

  • Prostate Cancer Diagnosis and Treatment14.6%
  • Prostate Cancer Treatment and Research12.7%
  • Bladder and Urothelial Cancer Treatments5.5%
  • Urinary Bladder and Prostate Research3.1%
  • Urinary and Genital Oncology Studies2.8%
  • Cancer Immunotherapy and Biomarkers2.2%
  • Other59.1%

Coauthors

All papers

Open in search
  1. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Clare Allen, Francesco Giganti, Alex Freeman, Stephen Morris, Shonit Punwani, Norman Williams, Chris Brew‐Graves, Jonathan J Deeks, Yemisi Takwoingi, Mark Emberton, Caroline M. Moore - New England Journal of Medicine 2018 cited by 3,016

  2. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marco Bolis, Fabio Grassi, Antonio Esposito, Matteo Bellone, Alberto Briganti, María Rescigno, Jean‐Philippe Theurillat, Christian Jobin, Silke Gillessen, Johann S. de Bono, Andrea Alimonti - Science 2021 cited by 322

  3. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 734

  4. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2018 cited by 388

  5. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Journal of Cancer 2023 cited by 157

  6. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies

    Authors: , , , , , , , , , , , , , , , , , , - European Urology 2018 cited by 315

  7. Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores

    Authors: , , , , , , , , , , , , - European Urology 2011 cited by 787

  8. A Systematic Review of the Association Between Erectile Dysfunction and Cardiovascular Disease

    Authors: , , , , , , - European Urology 2013 cited by 528

  9. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard

    Authors: , , , , , , , , , , , , , - European Urology Oncology 2021 cited by 119

  10. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Urology 2022 cited by 118

  11. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial

    Authors: , , , , , , , , , , , , , , , - Clinical Cancer Research 2022 cited by 111

  12. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2019 cited by 320

  13. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jacqueline Powers, Raoul S. Concepcion, Daniel W. Lin, Richard C. Wender, James Ryan Mark, Anthony J. Costello, Arthur L. Burnett, Oliver Sartor, William B. Isaacs, Jianfeng Xu, Jeffrey N. Weitzel, Gerald L. Andriole, Himisha Beltran, Alberto Briganti, Lindsey Byrne, Anne Calvaresi, Thenappan Chandrasekar, David Y.T. Chen, Robert B. Den, Albert Dobi, E. David Crawford, James A. Eastham, Scott E. Eggener, Matthew L. Freedman, Marc B. Garnick, Patrick T. Gomella, Nathan Handley, Mark Hurwitz, Joseph K. Izes, R. Jeffrey Karnes, Costas D. Lallas, Lucia R. Languino, Stacy Loeb, Ana María López, Kevin R. Loughlin, Grace Lu‐Yao, S. Bruce Malkowicz, Mark Mann, Patrick Mille, Martin Miner, Todd M. Morgan, José Moreno, Lorelei A. Mucci, Ronald E. Myers, Sarah M. Nielsen, Brock O’Neil, Wayne H. Pinover, Peter A. Pinto, Wendy Poage, Ganesh V. Raj, Timothy R. Rebbeck, Charles J. Ryan, Howard M. Sandler, Matthew J. Schiewer, Emily Scott, Brittany M. Szymaniak, William Tester, Edouard J. Trabulsi, Neha Vapiwala, Evan Y. Yu, Charnita Zeigler‐Johnson, Leonard G. Gomella - Journal of Clinical Oncology 2020 cited by 279

  14. The Microbiome of the Prostate Tumor Microenvironment

    Authors: , , , , , , , , , , , , , , , - European Urology 2017 cited by 249

  15. Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis

    Authors: , , , , , , , , , , , , , , - European Urology Oncology 2020 cited by 179

  16. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis

    Authors: , , , , , , , , , , , , - Annals of Oncology 2011 cited by 658

  17. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature

    Authors: , , , , , , , , , - European Urology 2015 cited by 786

  18. Distribution of metastatic sites in patients with prostate cancer: A population‐based analysis

    Authors: , , , , , , , , , , , - The Prostate 2013 cited by 564

  19. Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients

    Authors: , , , , , , , , , , , , , , , - European Urology Oncology 2020 cited by 97

  20. Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression

    Authors: , , , , , , , , , , , , , , , , , - Cell Reports 2018 cited by 95

  21. Positive Surgical Margins After Radical Prostatectomy: A Systematic Review and Contemporary Update

    Authors: , , , , , , - European Urology 2013 cited by 417

  22. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies

    Authors: , , , , , , , , , , , , , , , , , , , , - European Urology 2023 cited by 83

  23. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted Biopsy in Clinically Significant Prostate Cancer Detection Rate? A Systematic Review and Meta-analysis

    Authors: , , , , , , , , , , , , , , , - European Urology Oncology 2023 cited by 63

  24. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer

    Authors: , , , , , , , , - European Urology 2014 cited by 336